GB1584129A - Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system - Google Patents
Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system Download PDFInfo
- Publication number
- GB1584129A GB1584129A GB24400/78A GB2440078A GB1584129A GB 1584129 A GB1584129 A GB 1584129A GB 24400/78 A GB24400/78 A GB 24400/78A GB 2440078 A GB2440078 A GB 2440078A GB 1584129 A GB1584129 A GB 1584129A
- Authority
- GB
- United Kingdom
- Prior art keywords
- matrix
- mobile component
- solid phase
- reaction
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 59
- 238000002764 solid phase assay Methods 0.000 title description 3
- 238000002405 diagnostic procedure Methods 0.000 title description 2
- 238000000338 in vitro Methods 0.000 title description 2
- 238000006243 chemical reaction Methods 0.000 claims description 156
- 239000011159 matrix material Substances 0.000 claims description 125
- 239000007790 solid phase Substances 0.000 claims description 70
- 239000012530 fluid Substances 0.000 claims description 56
- 239000000427 antigen Substances 0.000 claims description 25
- 102000036639 antigens Human genes 0.000 claims description 25
- 108091007433 antigens Proteins 0.000 claims description 25
- 238000012360 testing method Methods 0.000 claims description 25
- 230000008569 process Effects 0.000 claims description 22
- 238000009739 binding Methods 0.000 claims description 19
- 238000009792 diffusion process Methods 0.000 claims description 19
- 230000027455 binding Effects 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 230000008859 change Effects 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 7
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 238000000465 moulding Methods 0.000 claims description 4
- 239000008199 coating composition Substances 0.000 claims description 2
- 230000002596 correlated effect Effects 0.000 claims description 2
- 239000000376 reactant Substances 0.000 description 36
- 238000003556 assay Methods 0.000 description 33
- 239000000523 sample Substances 0.000 description 30
- 239000000243 solution Substances 0.000 description 25
- 238000003746 solid phase reaction Methods 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- 230000008901 benefit Effects 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 230000000984 immunochemical effect Effects 0.000 description 13
- 238000011534 incubation Methods 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000004044 response Effects 0.000 description 11
- 238000008416 Ferritin Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000002245 particle Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 102000008857 Ferritin Human genes 0.000 description 6
- 108050000784 Ferritin Proteins 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 6
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000006555 catalytic reaction Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 229960005156 digoxin Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 4
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 4
- -1 i.e. Proteins 0.000 description 4
- 229920000193 polymethacrylate Polymers 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 229940034208 thyroxine Drugs 0.000 description 4
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000008057 potassium phosphate buffer Substances 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- JOJYUFGTMHSFEE-YONYXQDTSA-M Cytarabine ocfosphate Chemical compound [Na+].O[C@H]1[C@H](O)[C@@H](COP([O-])(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 JOJYUFGTMHSFEE-YONYXQDTSA-M 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 229910004861 K2 HPO4 Inorganic materials 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241001620634 Roger Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000006149 azo coupling reaction Methods 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000012205 qualitative assay Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000010671 solid-state reaction Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80548077A | 1977-06-10 | 1977-06-10 | |
| US05/805,431 US4197287A (en) | 1977-06-10 | 1977-06-10 | Method and apparatus for performing in nitro clinical diagnostic tests using a solid phase assay system having special utility for use with automatic pipetting equipment |
| US05/905,552 US4225575A (en) | 1978-05-15 | 1978-05-15 | Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1584129A true GB1584129A (en) | 1981-02-04 |
Family
ID=27420015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB24400/78A Expired GB1584129A (en) | 1977-06-10 | 1978-05-30 | Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS5463796A (enrdf_load_stackoverflow) |
| AU (1) | AU521002B2 (enrdf_load_stackoverflow) |
| CA (1) | CA1109791A (enrdf_load_stackoverflow) |
| DE (1) | DE2824742A1 (enrdf_load_stackoverflow) |
| DK (1) | DK257378A (enrdf_load_stackoverflow) |
| FR (1) | FR2394088A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1584129A (enrdf_load_stackoverflow) |
| SE (1) | SE446666B (enrdf_load_stackoverflow) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1982000058A1 (en) * | 1980-06-20 | 1982-01-07 | Porter P | Processes and apparatus for carrying out specific binding assays |
| GB2129551A (en) * | 1982-04-28 | 1984-05-16 | Mochida Pharm Co Ltd | Immunoassay vessel conveying analysis information |
| EP0111762A1 (en) * | 1980-06-20 | 1984-06-27 | Unilever Plc | Processes and apparatus for carrying out specific binding assays |
| US4742011A (en) * | 1984-03-15 | 1988-05-03 | Unilever Patent Holdings B.V. | Devices for carrying out chemical and clinical tests, and their use |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4305924A (en) * | 1979-08-08 | 1981-12-15 | Ventrex Laboratories, Inc. | Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system |
| US4378344A (en) * | 1979-09-28 | 1983-03-29 | Ventrex Laboratories, Inc. | Method and apparatus for performing multiple, simultaneous in vitro diagnostic tests using a solid phase system |
| ZA806976B (en) * | 1979-11-13 | 1981-10-28 | Ventrex Lab Inc | Method and apparatus for carrying out solid phase in vitro diagnostic assays |
| FI61965C (fi) * | 1980-01-17 | 1982-10-11 | Suovaniemi Finnpipette | Foerfarande foer detektering av hemoglobin i avfoering |
| DE3165750D1 (en) * | 1980-05-27 | 1984-10-04 | Secr Social Service Brit | Improvements in or relating to support means |
| EP0085276A1 (de) * | 1981-12-10 | 1983-08-10 | Greiner Electronics Ag | Verfahren zur immunchemischen Bestimmung einer Substanz |
| AU529210B3 (en) * | 1983-02-02 | 1983-04-14 | Australian Monoclonal Development Pty. Ltd. | Monoclonal antibody in occult blood diagnosis |
| US4657869A (en) * | 1984-05-18 | 1987-04-14 | E. I. Du Pont De Nemours And Company | Self-contained device for carrying out specific binding assays |
| DE69429159T2 (de) | 1993-02-01 | 2002-08-14 | Thermo Labsystems Oy, Helsinki | Verfahren für einen spezifischen Bindungstest mit magnetischen Teilchen |
| FI930440A0 (fi) * | 1993-02-01 | 1993-02-01 | Labsystems Oy | Bestaemningsfoerfarande |
| FI944940A0 (fi) * | 1994-10-20 | 1994-10-20 | Labsystems Oy | Tvaofasigt separeringsfoerfarande |
| FI944938A0 (fi) * | 1994-10-20 | 1994-10-20 | Labsystems Oy | Foerflyttningsanordning |
| FI944939A0 (fi) * | 1994-10-20 | 1994-10-20 | Labsystems Oy | Foerfarande foer separering av partiklar |
| FI944937A0 (fi) | 1994-10-20 | 1994-10-20 | Labsystems Oy | Separeringsanordning |
| SE0002820L (sv) * | 2000-08-04 | 2002-02-05 | Jordanian Pharmaceutical Mfg & | Medicinskt kit |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3826619A (en) * | 1971-12-21 | 1974-07-30 | Abbott Lab | Test apparatus for direct radioimmuno-assay for antigens and their antibodies |
| CH583422A5 (enrdf_load_stackoverflow) * | 1972-01-25 | 1976-12-31 | Hoffmann La Roche | |
| DE2438436B2 (de) * | 1974-08-09 | 1979-11-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Formgegenstand mit enzymatisch aktiver Oberfläche und Verfahren zu seiner Herstellung |
| US4020151A (en) * | 1976-02-17 | 1977-04-26 | International Diagnostic Technology, Inc. | Method for quantitation of antigens or antibodies on a solid surface |
| FI54842C (fi) * | 1977-01-14 | 1979-03-12 | Suovaniemi Finnpipette | Formstycke i anordningar foer immunitetsbestaemningar och enzymreaktioner |
| US4116638A (en) * | 1977-03-03 | 1978-09-26 | Warner-Lambert Company | Immunoassay device |
-
1978
- 1978-05-30 GB GB24400/78A patent/GB1584129A/en not_active Expired
- 1978-05-31 SE SE7806400A patent/SE446666B/sv not_active IP Right Cessation
- 1978-06-06 DE DE19782824742 patent/DE2824742A1/de active Granted
- 1978-06-08 FR FR787817166A patent/FR2394088A1/fr active Granted
- 1978-06-08 AU AU36927/78A patent/AU521002B2/en not_active Expired
- 1978-06-09 JP JP6972478A patent/JPS5463796A/ja active Pending
- 1978-06-09 CA CA305,110A patent/CA1109791A/en not_active Expired
- 1978-06-09 DK DK257378A patent/DK257378A/da not_active Application Discontinuation
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1982000058A1 (en) * | 1980-06-20 | 1982-01-07 | Porter P | Processes and apparatus for carrying out specific binding assays |
| EP0042755A3 (en) * | 1980-06-20 | 1982-01-27 | Unilever Plc | Processes and apparatus for carrying out specific binding assays |
| EP0111762A1 (en) * | 1980-06-20 | 1984-06-27 | Unilever Plc | Processes and apparatus for carrying out specific binding assays |
| GB2129551A (en) * | 1982-04-28 | 1984-05-16 | Mochida Pharm Co Ltd | Immunoassay vessel conveying analysis information |
| US4742011A (en) * | 1984-03-15 | 1988-05-03 | Unilever Patent Holdings B.V. | Devices for carrying out chemical and clinical tests, and their use |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2824742A1 (de) | 1979-02-15 |
| AU521002B2 (en) | 1982-03-11 |
| FR2394088B1 (enrdf_load_stackoverflow) | 1985-01-25 |
| JPS5463796A (en) | 1979-05-22 |
| AU3692778A (en) | 1979-12-13 |
| FR2394088A1 (fr) | 1979-01-05 |
| SE446666B (sv) | 1986-09-29 |
| DE2824742C2 (enrdf_load_stackoverflow) | 1989-08-31 |
| CA1109791A (en) | 1981-09-29 |
| DK257378A (da) | 1978-12-11 |
| SE7806400L (sv) | 1978-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4225575A (en) | Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system | |
| CA1141660A (en) | Immunoaassay with the same component on receptacle and insert | |
| US4197287A (en) | Method and apparatus for performing in nitro clinical diagnostic tests using a solid phase assay system having special utility for use with automatic pipetting equipment | |
| CA1149279A (en) | Method and apparatus for performing multiple, simultaneous in vitro diagnostic tests using a solid phase system | |
| CA1109791A (en) | Solid phase assay with one component immobilized on solid insert of high surface to volume ratio | |
| US4948726A (en) | Enzyme immunoassay based on membrane separation of antigen-antibody complexes | |
| EP0217403B1 (en) | Solid-phase analytical device and method for using same | |
| US4244694A (en) | Reactor/separator device for use in automated solid phase immunoassay | |
| US4425438A (en) | Assay method and device | |
| US4818677A (en) | Membrane assay using focused sample application | |
| US4623461A (en) | Transverse flow diagnostic device | |
| JP2818191B2 (ja) | 固相分析装置 | |
| US4338094A (en) | Macroencapsulated immunosorbent assay technique | |
| AU623354B2 (en) | Agglutination reaction device | |
| US4280816A (en) | Macroencapsulated immunosorbent assay technique and element therefor | |
| JPH087215B2 (ja) | 抗原および／又は抗体の検出方法および検出用の試験キット | |
| JPH03176659A (ja) | クロマトグラフィーストリップ結合アッセイ装置 | |
| JPS596390B2 (ja) | 実験分析装置 | |
| WO1987003690A1 (en) | Particle-bound binding component immunoassay | |
| US5869347A (en) | Particle immunoassay using a compact matrix | |
| US4708932A (en) | Method and device for biospecific affinity reactions | |
| EP0327786A1 (en) | Method and apparatus for carrying out chemical or biochemical reactions in porous carrier phases | |
| US4425320A (en) | Method and apparatus for carrying out solid phase in vitro diagnostic assays | |
| EP0308704A1 (en) | Heterogeneous enzymimmunoassay | |
| KR910001313B1 (ko) | 면역 분석 방법 및 장치 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |